Aeolus Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and first nine months ended June 30, 2017. For the quarter, the company announced contract revenue of $13,000 compared to $660,000 for the same period a year ago. Loss from operations was $949,000 compared to $872,000 for the same period a year ago. Net loss attributable to common stockholders was $949,000 compared to $872,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.01 compared to $0.01 for the same period a year ago. The decline in revenue is primarily attributable to a lower level of activity under the BARDA Contract. For the first nine months, the company announced contract revenue of $225,000 compared to $1,530,000 for the same period a year ago. Loss from operations was $3,071,000 compared to $2,250,000 for the same period a year ago. Net loss attributable to common stockholders was $3,071,000 compared to $5,021,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.02 compared to $0.03 for the same period a year ago. Net cash used in operating activities was $2,752,000 compared to $2,508,000 for the same period a year ago.